Stocksigma LogoStocksigma Logo

Novelix Pharmaceuticals Reports Nil Deviation in Preferential Issue Fund Utilization

Novelix Pharmaceuticals Limited submitted its Statement of Deviation or Variation for the quarter ended 30th Sep'26, reporting zero deviation in the

Novelix Pharmaceuticals Reports Nil Deviation in Preferential Issue Fund Utilization

Novelix Pharmaceuticals Ltd 路 Others (Uncategorized) 路 12 Nov 2026, 12:59 am

Novelix Pharmaceuticals Reports Nil Deviation in Preferential Issue Fund Utilization Novelix Pharmaceuticals Limited submitted its Statement of Deviation or Variation for the quarter ended 30th Sep'26, reporting zero deviation in the utilization of proceeds raised via preferential issue on 9th Jul'26. The company deployed Rs. 506.25 lakhs entirely toward long-term funding, working capital, and general corporate purposes. In a separate tranche of Rs. 684.00 lakhs, funds were utilized across land development (Rs. 104.00 lakhs utilized out of Rs. 188.00 lakhs allocated), land lease deposit (Rs. 100.00 lakhs), consumables (Rs. 100.00 lakhs), pre-operative expenses (Rs. 125.00 lakhs), technology transfer fees to GMBU Germany (Rs. 75.00 lakhs), quality control equipment (Rs. 61.00 lakhs), and travel expenses (Rs. 35.00 lakhs).

Original exchange filing (PDF)

More announcements from Novelix Pharmaceuticals Ltd

All Novelix Pharmaceuticals Ltd announcements